Sun et al [39] used an 85-gene NGS panel and analyzed paired tumor and plasma samples of 11 CRC patients, and results showed calculated sensitivity of 80% and specificity of 100% in the detection of KRAS status in cfDNA. This evidence concerns the gene KRAS and colorectal carcinoma.